ELKS/RAB6-interacting/CAST family member 1Genealiases: Cast2 · ELKS · ERC-1 · RAB6IP2
Q-omics provides the consensus-scored ERC1 profile across patient tissues and cancer cell-line models. ERC1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ERC1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ERC1 protein abundance shows 27,953 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight MESO, and HNSC as cancer lineages where ERC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERC1 survival associations across molecular data types. ERC1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERC1 RNA expression–survival associations across cancer types. High ERC1 expression shows unfavorable associations in MESO, BLCA and KICH, but favorable associations in SCLC, KIRC and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for ERC1 RNA expression.
This table summarizes ERC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 12. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ERC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERC1 shows lower tumor expression in BLCA, THCA and KICH and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher ERC1 RNA expression in tumor versus normal tissue (log2 FC = +0.812, t-test p < 0.001).
This table shows molecular features associated with ERC1 in patient tissues and cancer cell lines. In patient samples, ERC1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, ERC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
